Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: A prospective comparison of effectiveness and costs

American Journal of Perinatology

Volumn 13, Issue 7, 1996, Pages 423-429

  Durand Zaleski, Isabelle ^a   Schlegel, Nicole ^b   Blum Boisgard, Claudine ^c   Uzan, Serge ^e   Dreyfus, Marie ^f   Kaplan, Cecile ^d   Aujard, Y ^e   Baumann, C ^e   Blot, P ^e   Boissinot, C ^e   Daffos, F ^e   Fernandez, H ^e   Forestier, F ^e   Hurtaud Roux, F ^e   Oury, J F ^e   Pons, J C ^e   Tchernia, G ^e   Verdy, E ^e  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c ANDEM   (France)

^d INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^e HÔPITAL TENON   (France)

^f BICÊTRE HOSPITAL   (France)

Author keywords

Cost effectiveness analysis; Economics; Fetal diagnosis; Neonatal alloimmune thrombocytopenia; Screening

Indexed keywords

ADULT; ALLOIMMUNITY; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL DISEASE; NEWBORN DISEASE; PRIMIGRAVIDA; PRIORITY JOURNAL; SCREENING TEST; THROMBOCYTOPENIA;

ANTIGENS, HUMAN PLATELET; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; EPITOPES; FEMALE; FETAL DISEASES; HUMANS; INFANT, NEWBORN; MASS SCREENING; NEONATAL SCREENING; PARITY; PREGNANCY; PROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 0030468012     PISSN: 07351631     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994382     Document Type: Review

References (44)

1. Harrington WJ, Sprague CC, Minnich V, et al. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953;38:433-469.
2. Shulman R, Marder V, Hiller M, Collier E. Platelet and leukocyte isoantigens and their antibodies: Serologic, physiologic and clinical studies. In Moore C, Brown E (Eds.): Progress in Hematology. New York: Grune and Stratum, 1964, pp. 222-304.
3. van Loghem JJ Jr, Dorfmeijer H, van der Hart M, Schreuder F. Serological and genetical studies on a platelet antigen (Zw). Vox Sang 1959;4:161-169.
4. von dem Borne AEG, Decary F. Nomenclature of platelet specific antigens. Br J Haematol. 1990;74:239-240.
5. Mueller-Eckhart C, Kiefel V, Gruber A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1988;i:363-366.
6. Blanchette VS, Chen L, de Friedberg ZS, et al. Alloimmunization to the PLA1 platelet antigen: Results of a prospective study. Br J Haematol 1990;74:209-215.
7. Gafni A, Blanchette V. Screening for neonatal immune thrombocytopenia: An economic perspective. Curr Stud Hematol Blood Transfus 1988;54:410-447.
8. Kaplan C, Morel-Kopp MC, Kroll H, et al. HPA-5b(Bra) neonatal alloimmune thrombocytopenia: Clinical and immunological analysis of 39 cases. Br J Haematol 1991;78:425-429.
9. Valentin X, Vergracht A, Bignon JD, et al. HLA-DRw52a is involved in alloimmunization against P1-A1 antigen. Human Immunol 1990;27:73-79.
10. Decary F, L'Abbé D, Tremblay L, Chartrand P. The immune response to the HPA-1a antigen: Association with HLA-DRw52a. Transf Med 1991;1:55-62.
11. Bussel J, Kaplan C, McFarland J. Recommendations for the evaluation and treatment of neonatal autoimmune and alloimmune thrombocytopenia. Thromb Haemost 1991; 65:631-634.
12. Kaplan C, Morel-Kopp M, Clemenceau S, et al. Fetal and neonatal alloimmune thrombocytopenia: Current trends in diagnosis and therapy. Transf Med 1992;2:265-271.
13. Bussel JB, Berkowitz RL, McFarland JG, et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988;319:1374-1378.
14. Daffos F, Forestier F, Kaplan C. Prenatal treatment of fetal alloimmune thrombocytopenia, Lancet 1988;ii:910.
15. Daffos F, Forestier F, Muller J, et al. Prenatal treatment of alloimmune thrombocytopenia. Lancet 1984;ii:632.
16. Kaplan C, Daffos F, Forestier F, et al. Management of alloimmune thrombocytopenia: Antenatal diagnosis and in utero transfusion of maternal platelets. Blood 1988;72:340-343.
17. Waters A, Murphy M, Humbley H, Nikolaïdes K. Management of alloimmune thrombocytopenia in fetuses and neonates. In Nance SJ, (Ed.): Clinical and Basic Science; Aspects of Immunohematology. Arlington: American Association of Blood Banks, 1991, pp. 155-177.
18. Daffos F, Capella-Pavlosky M, Forestier F. Fetal blood sampling during pregnancy with use of a needle guided by ultrasound: A study of 606 consecutive cases. Am J Obstet Gynecol 1985;153:655-660.
19. Kroll H, Kiefel V, Giers G, et al. Maternal intravenous immunoglobulin treatment does not prevent intracranial hemorrhage in fetal alloimmune thrombocytopenia. Transf Med 1994;4:293-296.
20. Murphy M, Waters H, Doughty H, et al. Antenatal management of fetomaternal alloimmune thrombocytopenia - report of 15 affected pregnancies. Transf Med 1994;4:281-292.
21. Nicolini U, Tannirandorn Y, Gonzalez P, et al. Continuing controversy in alloimmune thrombocytopenia: Fetal hyperimmunoglobulinemia fails to prevent thrombocytopenia. Am J Obstet Gynecol 1990;163:1144-1146.
22. Lunch L, Bussel J, McFarland J. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol 1992;80:67-71.
23. Doughty HA, Murphy MF, Metcalfe P, Waters AH. Antenatal screening for fetal alloimmune thrombocytopenia: The results of a pilot study. BrJ Haematol 1995;90:321-325.
24. Soulier JP, Patereau C, Drouet J. Platelet indirect radioactive Coombs test: Its utilization for P1A1 grouping. Vox Sang 1975;29:253-268.
25. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhart C. Monoclonal antibody-specific immobilization of platelet antigens (MATPA): A new tool for the identification of platelet-reactive antibodies. Blood 1987;70:1722-1726.
26. Armitage P, Berry G. Statistical Methods in Medical Research (2nd ed). Oxford: Blackwell Scientific Publications, 1987, pp. 60-67.
27. Armitage P, Berry G. Statistical Methods in Medical Research (2nd ed). Oxford: Blackwell Scientific Publications, 1987, pp. 518-519.
28. Drummond M, Stoddart G, Torrance G. Methods for Economic Evaluation of Health Care Programs. Oxford: Oxford University Press, 1989, pp. 18-38.
29. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation. Ottawa: 1994.
30. Service des Statistiques, ds Etudes et ds Systèmes d'Information (SESI). Annuaire des statistiques sanitaires et sociales. Paris: Ministère de la Santé et de la Solidarité, 1991, pp.
31. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993; 329:1463-1466.
32. Flug F, Karpatkin M, Karpatkin S. Should all pregnant women be tested for their platelet PLA (Zw, HPA-1) phenotype? BrJ Haematol 1994;86:1-5.
33. Lancaster PAL. Assisted conception. Health services and evaluation. Intl J Technol Assess Health Care 1991;7: 485-499.
34. Tymstra T. Prenatal diagnosis, prenatal screening, and the rise of the tentative pregnancy. Intl J Technol Assess Health Care 1991,4:509-516.
35. Ramsey SD, Nettleman MD. Cost-effectiveness of prophylactic AZT following needlestick injury in health care workers. Med Decis Mak 1992;12:142-148.
36. Binkin NJ, Koplan JP. The high cost and low efficacy of weekly viral cultures for pregnant women with recurrent genital herpes: A reappraisal. Med Decis Mak 1989;9:225-230.
37. England WL, Halls JJ, Hunt VB. Strategies for screening for colorectal carcinoma. Med Decis Mak 1989;9:3-13.
38. Buhaug H. Problems and prospects in the economic evaluation of antenatal care. Intl J Technol Assess Health Care 1992;8(suppl. 1):49-56.
39. Goldman DP, Clarke AE, Garber AM. Creating the costliest orphan: The orphan drug act in the development of ceredase, Intl J Technol Assess Health Care 1992;8:583-597.
40. Light DW. Effectiveness and efficiency under competition: The Cochrane test. Brit Med J 1991;303:1253-1254.
41. Wilson J, Junger G. Principles and practice of screening for disease. WHO Public Health Paper 34, Geneva:WHO, 1968.
42. Hakama L. Screening for cancer of the uterine cervix. IARC Scientific Publications 76. Lyon: IARC, 1986.
43. Paidas M, Berkowitz R, Lynch L, et al. Alloimmune thrombocytopenia: Fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995;172:475-479.
44. Le Gales C, Moatti J-P. Searching for consensus through multicriteria decision analysis: Assessment of screening strategies for hemoglobinopathies in southern France. Intl J Technol Assess Health Care 1991;6:430-449.